Bionano Genomics, Inc. (BNGO): Price and Financial Metrics
BNGO Price/Volume Stats
| Current price | $2.93 | 52-week high | $30.10 |
| Prev. close | $3.03 | 52-week low | $2.79 |
| Day low | $2.89 | Volume | 400,500 |
| Day high | $3.03 | Avg. volume | 859,442 |
| 50-day MA | $3.81 | Dividend yield | N/A |
| 200-day MA | $9.29 | Market Cap | 103.57M |
BNGO Stock Price Chart Interactive Chart >
BNGO POWR Grades
- Value is the dimension where BNGO ranks best; there it ranks ahead of 57.63% of US stocks.
- The strongest trend for BNGO is in Value, which has been heading up over the past 177 days.
- BNGO ranks lowest in Quality; there it ranks in the 2nd percentile.
BNGO Stock Summary
- For BNGO, its debt to operating expenses ratio is greater than that reported by just 12.13% of US equities we're observing.
- In terms of volatility of its share price, BNGO is more volatile than 96.7% of stocks we're observing.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for BNGO comes in at -53.81% -- higher than that of just 10.26% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to BIONANO GENOMICS INC, a group of peers worth examining would be IBIO, NSPR, HLGN, NSTG, and SERA.
- BNGO's SEC filings can be seen here. And to visit BIONANO GENOMICS INC's official web site, go to www.bionanogenomics.com.
BNGO Valuation Summary
- BNGO's price/earnings ratio is -0.7; this is 102.62% lower than that of the median Healthcare stock.
- Over the past 62 months, BNGO's EV/EBIT ratio has gone up 3.2.
Below are key valuation metrics over time for BNGO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BNGO | 2023-09-22 | 3.3 | 0.5 | -0.7 | -0.7 |
| BNGO | 2023-09-21 | 3.3 | 0.5 | -0.7 | -0.7 |
| BNGO | 2023-09-20 | 3.4 | 0.5 | -0.7 | -0.7 |
| BNGO | 2023-09-19 | 3.4 | 0.5 | -0.7 | -0.7 |
| BNGO | 2023-09-18 | 3.4 | 0.5 | -0.7 | -0.7 |
| BNGO | 2023-09-15 | 3.6 | 0.5 | -0.8 | -0.8 |
BNGO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BNGO has a Quality Grade of D, ranking ahead of 7.91% of graded US stocks.
- BNGO's asset turnover comes in at 0.063 -- ranking 71st of 75 Measuring and Control Equipment stocks.
- 500 - Internal server error
The table below shows BNGO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.063 | 0.333 | -3.723 |
| 2021-03-31 | 0.082 | 0.336 | -2.825 |
| 2020-12-31 | 0.230 | 0.326 | -4.176 |
| 2020-09-30 | 0.248 | 0.369 | -6.041 |
| 2020-06-30 | 0.352 | 0.344 | -2.947 |
| 2020-03-31 | 0.402 | 0.312 | -2.104 |
BNGO Price Target
For more insight on analysts targets of BNGO, see our BNGO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $11.50 | Average Broker Recommendation | 1.12 (Strong Buy) |
Bionano Genomics, Inc. (BNGO) Company Bio
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system includes an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Latest BNGO News From Around the Web
Below are the latest news stories about BIONANO GENOMICS INC that investors may wish to consider to help them evaluate BNGO as an investment opportunity.
Benchmarking Study Shows Streamlined Structural Variant Detection and High Concordance for OGM Compared to Chromosomal Microarray Analysis, the Global Standard in Genetic Disease AnalysisSAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed benchmarking study to compare optical genome mapping (OGM) to the current global standard in molecular analysis of constitutional genetic disorders, chromosomal microarray analysis (CMA). The study evaluated the potential of OGM to measure all classes of variant types covered by CMA, including gains, losses, aneuploidy, triploidy and absence of heterozygo |
Ticking Time Bombs: 3 Biotech Stocks to Dump Before the Damage Is DoneInvestors should do their due diligence before investing in these three risky, unreliable and unprofitable biotech stocks. |
Bionano Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that on September 18, 2023, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted an inducement award consisting of a non-qualified stock option to purchase 106,000 shares of common stock to Gülsen Kama, the Company’s new Chief Financial Officer, under the Company’s 2020 Inducement Plan, as amended. The Compensation Committee approved the award as an |
Bionano Genomics, Inc. (BNGO) Upgraded to Buy: Here's What You Should KnowBionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Bionano Announces Third OEM Partner has Received China NMPA Approval for DNA Isolation Products for IVD Use of OGMBionano original equipment manufacturing (OEM) partner Ecobono obtained reagent Class I registration and approval for Bionano’s DNA isolation kits for optical genome mapping (OGM) from China's National Medical Products Administration (NMPA)Reagents can be utilized for in vitro diagnostics (IVD) use in ChinaWith this NMPA registration, Ecobono can sell OGM reagents to independent clinical laboratories and Chinese hospitals SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasd |
BNGO Price Returns
| 1-mo | -23.90% |
| 3-mo | -53.57% |
| 6-mo | -72.10% |
| 1-year | -83.72% |
| 3-year | -52.74% |
| 5-year | -95.71% |
| YTD | -79.93% |
| 2022 | -51.17% |
| 2021 | -2.92% |
| 2020 | 148.39% |
| 2019 | -76.34% |
| 2018 | N/A |
Continue Researching BNGO
Want to see what other sources are saying about Bionano Genomics Inc's financials and stock price? Try the links below:Bionano Genomics Inc (BNGO) Stock Price | Nasdaq
Bionano Genomics Inc (BNGO) Stock Quote, History and News - Yahoo Finance
Bionano Genomics Inc (BNGO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...